RNXT News and Press, RenovoRx Inc. From 08/15/25

A look at the top 10 most actives in the United States Perfect Moment Ltd. (PMNT) rose 106.3% to $0.599001 on volume of 191,885,956 shares Dragonfly Energy Holdings Corp (DFLI) rose 36.2% to $0.361 on volume of 124,421,993 shares Opendoor Technologies Inc (OPEN) rose 4.6% to $3.18 on volume...

2025-08-14 16:25:20 ET More on RenovoRx Seeking Alpha’s Quant Rating on RenovoRx Historical earnings data for RenovoRx Financial information for RenovoRx Read the full article on Seeking Alpha For further details see: RenovoRx GAAP EPS of -...

Revenue from RenovoCath ® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Management to host conference call today at 4:30 p.m. ET RenovoRx, Inc . (“R...

Century Therapeutics Inc. (IPSC) is expected to report $-0.38 for Q2 2025 Birchtech Corp Com (BCHT) is expected to report for Q2 2025 Cellectar Biosciences Inc. (CLRB) is expected to report $-3.6 for Q2 2025 Acuren Corporation (TIC) is expected to report for quarter end 2025-06-30 ...

RenovoRx Inc. (RNXT) is expected to report $-0.08 for Q2 2025

RenovoRx increases its commercial footprint to thirteen leading National Cancer Institute-designated and community centers approved to purchase RenovoCath Four active cancer center customers are currently purchasing and have made repeat orders of RenovoCath for interventional radiology pr...

Malibu, CA, United States (ABN Newswire) - In this edition of The Ellis Martin Report and Money Talk Radio, we sit down with Shaun Bagai, Chief Executive Officer of RenovoRx, Inc. (NASDAQ:RNXT), a clinical-stage biopharmaceutical company pioneering a targeted, localized approach to treat hard-to-...

Several Esteemed Cancer Centers to Commence Patient Enrollment Before the End of September The Registry Study, Known as PanTheR, will Expand the Safety and Performance Data of the FDA-Cleared RenovoCath ® Device, and its Associated Survival Outcomes in Patients Diagnosed with Sol...

RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath ® , a novel, FDA-cleared drug-delivery device, today announced it will host its sec...

2025-05-15 21:07:13 ET RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call May 15, 2025, 04:30 PM ET Company Participants Valter Pinto - IR Ramtin Agah - Founder and Chief Medical Officer Shaun Bagai - CEO Ronald Kocak - VP Controller and Pri...